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i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 6 1 6 – 6 2 6 621competence in information technology, there are no web-
based disease registries for CVDs.2
I feel, the author, along with stressing on the need for
Indian guidelines, should have focused also on streamlining
the total health care system, because if health care system is
not streamlined with more focus on public healthy care,
guidelines whether Indian or otherwise will be affecting only
the miniscule population.
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Comment on ‘‘Prospective study to evaluate safety and
efﬁcacy of Zotarolimus Eluting Stent (PSEZES) in
patients with long coronary artery lesions’’Sir,
I read with interest the research article titled ‘‘Prospective
study to evaluate safety and efﬁcacy of Zotarolimus Eluting
Stent (PSEZES) in patients with long coronary artery lesions’’
by Bahuleyan et al.1 Heart of the matter is how safe is long
stents in the treatment of coronary artery disease (CAD), either
in acute or chronic condition. Numerous trials have demon-
strated that PCI may reduce symptoms ischemia, save lives,
and prevent myocardial infarction (MI) in either condition. The
longer the stent length, it is more difﬁcult to ensure its long-
duration patency. The thumb rule is that with each 1 mm
increase in stent length, the restenosis rate is increased by 1%.There are signiﬁcant gradients across the outcomes, as lesion
features change from type A to C. Even type C is not singular
but a family of difﬁcult lesions, and each one poses a unique
challenge during procedure and follow-up. The residual
platelet activity needs individual tailoring in the type of
antiplatelet and its dose2 with other medications rightly in
place in the prescription in a patient with good compliance.
The procedure itself, and the immediate and the late outcome
of every PCI done, are highly affected by the proﬁle of the
patient, lesion category, the chosen stent, skill of the operator,
and not the least by appropriately chosen antiplatelet. The
immediate and late adverse events, such as stent thrombosis
(ST) and target lesion revascularization (TLR), are continuous
hazards, and those should be the primary targets for
developing improved long-term patency of coronary
stents.3–5 Sometimes, target vessels react in form of dissection
in the ostium and in the edge in the context of intervention of
complex lesions or using unusual hardware. When compared
to LAD and RCA, PCI of complex lesion in LCX is associated
with lower procedural success, higher complication rates, and
less long-term patency.6 Therefore, in search of incremental
safety of stent in coronary disease, the research timeline
touches POBA, BMS, DES, biodegradable polymer, and BVS.
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 6 1 6 – 6 2 6622In this article, Bahuleyan et al.1 have stated that the
procedure was successful in 100% of cases and 1-year MACE,
rate of death, MI, and TLR were low with no incidence of
ST. The binary restenosis and angiographic in-stent late
lumen loss were comparable. But this concluding remark
needs further discussion before its translation into clinical
practice.
There are several limitations in this study. The study
suffers from limited study population, as also the number of
lesions, which the author has already alluded to. Most of the
members of the cohort belong to middle age, with 60% of them
presented with ACS. The clinical proﬁle did not include ECG,
biomarker, ejection fraction, which could have added incre-
mental information for risk stratiﬁcation. In this context, the
higher risk is associated with more complex lesions with
unfavorable outcomes even in cases of stable angina. The
atheromatous plaque in chronic stable angina offers more
difﬁcult tactile feeling because of more calciﬁc, ﬁbrotic, and
tortuous lesion.7 Therefore, the result in this study is skewed
in the favor of superior outcomes because most of the patients
are with ACS. There were less than ﬁve lesions that needed a
stent length of more than 35 mm. Most of the lesions were
conﬁned to LAD. The author has not mentioned the antiplate-
let regimens and the status of residual platelet activity because
there is difference in the prognosis in the selection of proper
antiplatelet, both in ACS and chronic stable angina.8,9 It is
presumed that patients treated with ticagrelor or pasugrel do
better. The author had more than 50% cases with true
bifurcation lesion in which the side branches needed wire. I
feel the author should have at least mentioned Medina
classiﬁcation. Last but not the least the major limitation of
this study is limited follow-up despite use of DES of average
length of 24 mm.
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